Drug Trial Radar · NCT06049095
A Phase 1 Single and Multiple Ascending Dose Study of LTG-001 Administered Orally in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Jun 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
204
Planned (sponsor's estimate)
Start
Oct 17, 2023
Primary completion
Sep 2026
Study completion Sep 2026
Sponsor
- Lead sponsor
- Latigo BiotherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Sep 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a sequential, randomized, double-blind, placebo-controlled Phase 1 single (SAD) and multiple (MAD) ascending dose study to evaluate the safety, tolerability, and pharmacokinetics (PK) of orally or intravenously administered LTG-001 in healthy male and female participants
Conditions
- Healthy
Interventions
LTG-001Drug
Oral doses
PlaceboDrug
Oral doses
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the safety and tolerability of single and multiple ascending oral doses, relative bioavailability and food effect of LTG-001 in healthy subjectsTime frame: Up to 10 days of dosing
- Absolute Bioavailability of LTG-001 Following Oral and Intravenous AdministrationTime frame: from admission to completion in the study (35 days)
- Safety and Tolerability of Intravenous LTG-001Time frame: From first intravenous dose through end of study (up to 14 days following intravenous dosing)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinical Research Unit
Christchurch, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.